Legal & RegulatoryEvent: September 1, 2026
Juniper Biosciences received Breakthrough Therapy designation from the FDA in partnership with MSKCC for its Phase III program.
Published
Signal category
Legal & Regulatory
Quote
“FDA has granted Breakthrough Therapy designation to our Phase III program in partnership with MSKCC”
— Alex Agnoletto|Juniper Biosciences team
Company
Juniper Biosciences
Developing innovative radiopharmaceutical products for the future of patient care
- Industry
- Pharmaceutical Manufacturing
- Location
- Bedminster, US
- Company size
- 10 employees
Juniper Biosciences is a radiopharmaceutical company focused on developing its pipeline of innovative products
Founded 2025